GlassScriptPhysician profile
David F Corral
NPI 1003846882
$1,397.14
in general payments reported to CMS, 2019-2025
11 companies · $35.28 in 2025
The $35.28 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $95.96 · 2021: $90.34 · 2022: $461 · 2023: $315 · 2024: $95.01 · 2025: $35.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $404.98 | 2019-2023 | Repatha |
| Abbott Laboratories | $345.24 | 2021-2022 | |
| Nevro Corp. | $182.37 | 2023 | Senza |
| Allergan, INC. | $171.79 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.35 | 2019 | |
| Haemonetics Corporation | $80.39 | 2024 | Teg6s Hemostasis System |
| Glaxosmithkline, LLC. | $25.02 | 2023 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $20.82 | 2025 | Orgovyx |
| Astellas Pharma US INC | $16.10 | 2020 | |
| Novo Nordisk INC | $14.62 | 2024 | Rybelsus, Ozempic |
| Globus Medical, INC. | $14.46 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Corral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.